CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 12 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02523040
NCT02523040Phase 2Active
CompareCT.gov

A Phase II Study of Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute·interventional·Posted Aug 14, 2015·Updated Dec 10, 2025

In Brief

A Phase 2 clinical trial evaluating Lenalidomide for Langerhans Cell Histiocytosis (LCH) and 2 related conditions. Active but no longer recruiting, targeting 12 participants across 1 site.

Detailed Summary

This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLangerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS)
CountriesUnited States
CollaboratorsCelgene

Timeline

Phase 2ActiveOverdue
20162017201820192020202120222023202420252026
First PostedAug 14, 2015
Enrollment StartAug 1, 2015
Primary CompletionFeb 1, 2024
Study CompletionFeb 1, 2026
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 10.9 years ago

Interventions

Lenalidomidedrug